• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Global Health >The need to implement non-industry COVID-19 clinical trials in non-high-income countries
【24h】

The need to implement non-industry COVID-19 clinical trials in non-high-income countries

机译：需要在非高收入国家实施非行业Covid-19临床试验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The COVID-19 pandemic is currently being managed globally using public health measures to contain and mitigate its impact. The COVID-19 spares no national boundaries and is spreading rapidly in both high-income and non-high-income countries [1]. The lack of approved therapies and the absence of a vaccine for COVID-19 have led to the repositioning of some existing medications with well-defined benefit-risk profiles in other indications. It is important to note that none of these medications have sufficient evidence on benefit-risk in COVID-19 patients, and should therefore be considered as experimental therapies, with an urgent need to collect data that will facilitate or prevent their use in COVID-19 patients – something that is already happening in many countries [2].
机译：Covid-19流行目前正在全球管理，使用公共卫生措施来包含和减轻其影响。 Covid-19没有国家边界，并且在高收入和非高收入国家迅速蔓延[1]。缺乏批准的疗法和缺乏Covid-19疫苗导致了在其他适应症中具有明确的益处风险概况的一些现有药物的重新定位。重要的是要注意，这些药物都没有足够的证据有关Covid-19患者的益处风险，因此应被视为实验疗法，迫切需要收集将促进或防止他们在Covid-19中使用的数据患者 - 许多国家已经发生的东西[2]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号